Clinical Trials Directory

Trials / Sponsors / Bioverativ, a Sanofi company

Bioverativ, a Sanofi company

Industry · 16 registered clinical trials.

StatusTrialPhaseStarted
CompletedTo Assess the Pharmacokinetics and Safety and Tolerability of Efanesoctocog Alfa (BIVV001)in Adults With Type
Von Willebrand's Disease (VWD)
Phase 12021-05-03
CompletedProof-of-concept Study for SAR445088 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Phase 22021-04-28
TerminatedSafety and Tolerability Study in Adults With Cold Agglutinin Disease Previously Treated With SAR445088 or Neve
Autoimmune Haemolytic Anaemia
Phase 12021-03-22
Active Not RecruitingLong-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia A
Hemophilia A
Phase 32021-02-23
CompletedSafety, Efficacy and PK of BIVV001 in Pediatric Patients With Hemophilia A
Hemophilia A
Phase 32021-02-19
CompletedA Phase 2a Study Evaluating BIVV020 in Adults With Persistent/Chronic Immune Thrombocytopenia (ITP)
Immune Thrombocytopenia (ITP)
Phase 22021-02-04
CompletedA Safety and Tolerability Study of BIVV020 in Adults With Cold Agglutinin Disease
Autoimmune Haemolytic Anaemia
Phase 12020-06-15
CompletedA Phase 3 Open-label Interventional Study of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand
Factor VIII Deficiency
Phase 32019-11-19
CompletedA Study to Assess the Efficacy and Safety of BIVV009 (Sutimlimab) in Participants With Primary Cold Agglutinin
Cold Agglutinin Disease
Phase 32018-03-17
CompletedA Study to Assess the Efficacy and Safety of BIVV009 (Sutimlimab) in Participants With Primary Cold Agglutinin
Agglutinin Disease, Cold
Phase 32018-03-05
CompletedA Study to Evaluate Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Participa
Hemophilia A With Inhibitors
Phase 42017-12-08
CompletedA Safety, Tolerability, and Pharmacokinetics Study of a Single Intravenous Injection of Recombinant Coagulatio
Hemophilia A
Phase 1 / Phase 22017-08-28
CompletedA Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple- Dose BIVV009 in Par
Purpura, Thrombocytopenic, Idiopathic
Phase 12017-08-14
CompletedSafety, Tolerability and Activity of BIVV009 in Healthy Volunteers and Patients With Complement Mediated Disor
Bullous Pemphigoid (BP), Cold Agglutinin Disease (CAD), Warm Autoimmune Hemolytic Anemia (WAIHA)
Phase 12015-07-13
CompletedAn Open Label Study to Determine the Safety and Efficacy of Replacement Factor VIII Protein (Known as rFVIIIFc
Hemophilia A
Phase 32015-01-12
CompletedStudy to Determine the Safety and Efficacy of rFIXFc in Previously Untreated Males With Severe Hemophilia B
Hemophilia B
Phase 32014-11-13